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Abstract: Amyotrophic lateral sclerosis (ALS) is a terminal late-onset condition characterized by
the loss of upper and lower motor neurons. Mutations in more than 30 genes are associated to the
disease, but these explain only ~20% of cases. The molecular functions of these genes implicate a
wide range of cellular processes in ALS pathology, a cohesive understanding of which may provide
clues to common molecular mechanisms across both familial (inherited) and sporadic cases and could
be key to the development of effective therapeutic approaches. Here, the different pathways that
have been investigated in ALS are summarized, discussing in detail: mitochondrial dysfunction,
oxidative stress, axonal transport dysregulation, glutamate excitotoxicity, endosomal and vesicular
transport impairment, impaired protein homeostasis, and aberrant RNA metabolism. This review
considers the mechanistic roles of ALS-associated genes in pathology, viewed through the prism of
shared molecular pathways.
Keywords: oxidative stress; mitochondria dysfunction; axonal transport; autophagy; endocytosis;
secretion; excitotoxicity; RNA metabolism; MND
1. Introduction
Amyotrophic lateral sclerosis (ALS) is the most frequent motor neuron disease (MND), with an
estimated ~223,000 patients being affected globally in 2015 [1]. The pathology affects both upper motor
neurons (UMN) in the cortex and lower motor neurons (LMN) in the brainstem and spinal cord [2].
Paralysis and death usually occur between three to four years after symptom onset [3], and there are
currently no effective treatments to slow disease progression [4]. Approximately 90% of ALS cases are
sporadic, while 10% are familial, defined by the occurrence of ALS in more than one family member [5].
Around 30 different genes are linked with ALS [5,6], explaining ~20% of all ALS cases and associated
with different molecular functions and disease phenotypes [7], so that the task of understanding the
relationships between affected pathways is complex.
To investigate the different molecular pathways affected in ALS, various in vivo models, including
drosophila [8–11], C-elegans [12], zebrafish [13–16], and rodents [17], as well as in vitro cell models such
as patient lymphoblastoid cell lines [18] and hybrid [19,20] or primary murine cell lines, [21] have been
developed. Most of these models investigate the pathological effects of mutations to ALS genes, including
Fused in Sarcoma (FUS), Superoxide dismutase (SOD1), TAR DNA-binding protein 43 (TDP-43), and Chromosome
9 open reading frame 72 (C9orf72) [22,23]. Their study has resulted in numerous cellular and molecular
mechanisms being proposed to explain motor neuron death. Mechanisms frequently implicated include:
reactive oxygen species (ROS)-associated oxidative stress [24–27], mitochondrial dysfunction [24], axonal
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and vesicular trafficking dysregulation [28,29], glutamate-mediated excitotoxicity [30–33], proteostatic
impairments [34–38], and altered RNA metabolism and/or processing [39–42].
Alteration to one or more of these cellular processes may be present, not only in the motor neurons
themselves but, also, in neighboring cell populations, such as glial cells, peripheral inflammatory
cells, and muscles, as ALS is increasingly considered a multisystemic disease that culminates in
motor neuron death [6,24]. For example, astrocytes and microglia have been implicated in the
release of proinflammatory mediators that lead to chronic neuroinflammation and motor neuron
toxicity [43]. In addition, the selective overexpression of mutant SOD1 in skeletal muscle was shown to
cause mitochondrial abnormalities, induce microglial activation in the central nervous system (CNS),
and result in severe muscle atrophy in mice [44].
Consensus is yet to be reached regarding the causal mechanisms involved in the onset and
propagation of ALS. The aim of this review is to identify and summarize the different molecular
mechanisms implicated in various forms of the disease, including sporadic and familial cases. In doing
so, it is hoped that new insights may be gained regarding the role of different pathways across different
forms of the disease.
2. Oxidative Stress
Oxidative stress results from an imbalance between the production and elimination of reactive
oxygen species (ROS) [45], as well as an impaired ability to repair ROS-mediated toxicity [46], and has
been of particular interest in ALS pathogenesis ([47] and Figure 1) since the discovery of SOD1
mutations in familial forms of ALS [48]. Increased levels of oxidized proteins, RNA, DNA, and lipids
have been observed in post-mortem tissue from both sporadic and SOD1 ALS cases [27,49,50], as well
as in the cerebrospinal fluid (CSF), serum, and urine of sporadic ALS patients [26].
SOD1 is a major antioxidant enzyme that is ubiquitously expressed and catalyzes radical
superoxide anions into molecular oxygen and hydrogen peroxide [51]. Approximately 80 of the 160
SOD1 mutations reported in ALS are missense mutations that fail to cause a loss of SOD1 activity [52],
and many SOD1 mouse models show a progressive, late-onset motor phenotype with concomitant
astrogliosis and motor neuron pathology when mutated forms of human SOD1 are overexpressed [17].
Evidence from human samples have shown that there is a 42% reduction in overall SOD1 activity
in familial SOD1 patients [53], potentially leading to an imbalance between ROS production and
degradation (Figure 1). This imbalance might be exacerbated by the disruption of the NRF2-ARE
(Nuclear erythroid 2-Related Factor—antioxidant response element) signaling pathway that is observed
in SOD1 ALS [54], thus affecting the expression of antioxidant proteins [55] (Figure 1). Supporting these
hypotheses, oxidative damage such as protein glycoxidation and lipid peroxidation were observed in
the motor neurons of the anterior horn from SOD1 familial ALS (fALS) patients [56] and SOD1G93A
mice [57,58].
The generation of ROS could result from the activity of NADPH oxidase in the lipid raft membrane
compartment. Interestingly, the ATXN2 gene encodes the ataxin-2 polyglutamine (PolyQ) protein,
and intermediate-length PolyQ expansions (27–33 Qs), which are known to be a significant risk for
ALS [59–61], can interact with NADPH oxidase and may lead to an increase in ROS production, DNA
damage, and mitochondrial distress [62] (Figure 1).
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Figure 1. Oxidative stress, mitochondrial dysfunction, axonal transport, and glutamate excitotoxicity in 
amyotrophic lateral sclerosis (ALS). An increase in oxidative stress can result from defects in detoxifying 
pathways. Such defects include the loss of SOD1 function, aberrant DNA damage repair machinery, or a decrease 
in expression of antioxidant genes affecting the NRF2-ARE pathway. Oxidative stress can also be increased by 
the stimulation of ROS production via increased NADPH oxidase activity or from disrupted mitchondrial 
respiratory chain activity. Mitochondrial activity can be affected by several ALS mutations, such as those leading 
Figure 1. Oxidative stress, mitochondrial dysfuncti n, axonal transport, and glutamate excitotoxicity in
amyotrop ic lateral scl rosis (ALS). An increase in xidative stress can result from defects in d toxifying
pathways. Such defects include the loss of SOD1 function, aberrant DNA damage repair machinery, or a
decrease in expression of antioxidant genes affecting the NRF2-ARE pathway. Oxidative stress can also be
increased by the stimulation of ROS production via increased NADPH oxidase activity or from disrupted
mitchondrial respiratory chain activity. Mitochondrial activity can be affected by several ALS mutations,
such as those leading to the accumulation of protein aggregates, or to decreased mitochondrial biogenesis
and transport, or to increased cytosolic Ca2+ (as observed when glutamate receptor activity is stimulated or
when the Ca2+-buffering capacity is decreased). Consequently a disruption of the mitochondrial respiratory
chain will lead to an increase in ROS production and, thus, to an accumulation of oxidized proteins, lipids,
DNA, and RNA. Oxidative damage occurring over time may then stimulate apoptotosis and, thus, cell death.
Defective axonal transport affects not only the mitochondria but, also, the transport of other proteins and RNA,
with consequences on the axon structure and function being accompanied by neurofilament accumulation.
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Defective glutamate uptake by astrocytes, and/or a defect in glutamate receptor clearance or
in AMPA or GABA receptors, can lead to increased Ca2+ permeability and can impact the
post-synaptic hyperexcitability and mitochondrial function. ARE: antioxidant response element,
AMPA2: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 2, ATXN2: ataxin 2, Bcl2:
B-cell lymphoma 2, C9orf72: Chromosome 9 open reading frame 72, C21orf2: Chromosome 21
open reading frame 7, CHCHD10: coiled-coil helix coiled-coil helix domain-containing 10, DCTN1:
Dynactin 1, EEAT2: Excitatory amino acid transporter, ER: endoplasmic reticulum, FUS: Fused
in Sarcoma, GABA: gamma-Aminobutyric acid, GlyR: glycine receptor, GlyT: glycine transporter,
KIF5A: Kinesin heavy-chain isoform 5A, MAM: Mitochondria-associated ER membranes, NEFH:
heavy-weighted neurofilaments, NEK1: (NIMA)-related kinase 1, NMDA: N-methyl-D-aspartate
receptor, NRF2: Nuclear erythroid 2-Related Factor, PFN1: profilin-I, PTPIP51: Protein tyrosine
phosphatase-interacting protein 51, SETX: senataxin, SOD: Superoxide dismutase 1, SPG11: Spatacsin,
TDP-43: TAR DNA-binding protein 43, VAPB: vesicle-associated membrane protein-associated protein
B, VCP: valosin-containing protein, and ROS: reactive oxygen species.
Recurrent oxidative stress and/or mitochondrial dysfunction occurring throughout the life of
the cell can lead to DNA damage—damage that can be fixed by activating the DNA damage repair
machinery. Several genes known to encode for proteins involved in DNA damage repair [63–65]
are also associated with ALS: NEK1 [66], C21orf2 [67], and SETX [68]. These encode for the proteins
never in mitosis-A (NIMA)-related kinase 1 (NEK1), cilia and flagella-associated protein 410, and the
DNA/RNA helicase senataxin, respectively. Mutations in these genes may therefore increase the
susceptibility to ALS as a result of dysregulated DNA damage repair machinery [67,69,70], leading
to an impaired ability of motor neurons to cope with oxidative stress, consequently leading to cell
death [64,70] (Figure 1). For example, induced pluripotent stem cell (iPSC) motor neurons derived from
NEK1c.2434A>T-mutated ALS patients exhibit an increased level of DNA damage, as well as a failure
to repair DNA double-strand breaks [70]. Primary motor neurons from SETXR2136H and SETXL389S
murine models were unable to cope with induced oxidative stress and showed an increased stress
granule formation [71].
Altogether, these studies suggest that oxidative stress might be increased in sporadic and familial
ALS patients. Increased oxidative stress may affect mitochondrial function [72], exacerbate endoplasmic
reticulum stress [73], and impact protein homeostasis mechanisms [74], ultimately leading to cell
damage and neuronal loss.
3. Mitochondrial Dysfunction
Mitochondria are key organelles for ATP generation, calcium buffering, and apoptosis
regulation [75], and their dysfunction in the dorsal root ganglion cells of sporadic ALS patients
has been described previously [76]. Several mechanisms can trigger mitochondrial dysfunction in ALS
(Figure 1).
The maintenance of mitochondrial cristae organization is crucial to ensure respiratory chain
function [77] and requires cardiolipin, the ATP synthase dimer, and large protein complexes such as the
mitochondrial contact site complex (MICOS) and dynamin-like Opa1/Mgm1 [78,79]. The coiled-coil
helix coiled-coil helix domain-containing protein 10 (CHCHD10), known to be associated with ALS [23],
is suspected to be either part of [80,81] or interact with MICOS [82]. Consequently, mutations in
CHCHD10 result in the loss of mitochondria cristae [80], mitochondria fragmentation [81], and defective
mitochondrial repair [80,83] (Figure 1).
Mitochondrial biogenesis can also be directly affected, as observed in FUS-mutated conditions [84,85].
While FUS encodes for a DNA/RNA-binding protein [86] predominantly localized to the nucleus, mutated
forms of FUS can accumulate in the cytosol and possibly become toxic [87,88] and affect the mitochondrial
function. For example, the mutated FUSP525L can interact with mitochondrial chaperone proteins and
induce mitochondria fragmentation and elevated ROS production [84,85].
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Aberrant swollen mitochondria morphology has also been observed in neuronal, non-neuronal
cells, and muscle tissue of other fALS cases, such as SOD1 [24,89] and C9orf72 [25,89]-mutated
ALS patients but, also, in both SOD1G93A and TDP-43A315T murine models [44,90,91]. The aberrant
morphology may result from a cascade of events involving the mutated protein aggregates. For
example, insoluble mutant SOD1 can aggregate in mitochondria in the spinal cord of SOD1G93A
mice [92], causing the formation of vacuoles in the outer- and inter-mitochondrial membrane [93],
affecting mitochondrial respiration, energy production, and ultimately, increasing the level of oxidative
stress [94] (Figure 1). ALS patients with the SOD1A4V mutation show significant increases in complex I
and III activity of mitochondria in the motor cortex [95,96]. The overactivation of complexes I and III
increased the production of mitochondrial ROS [97] and may explain the high level of oxidative stress
observed in SOD1 mice and patients.
The G4C2 hexanucleotide repeat expansion mutation (HREM) in the C9orf72 gene explains
40–50% of familial ALS cases and 5–10% of sporadic cases [98–101]. There are several hypotheses
regarding the mechanisms by which this leads to toxicity, and evidence exists for both loss and
gain-of-function-mediated toxicity. One hypothesis suggests that the repeat-associated non-AUG (RAN)
translation of G4C2 repeats is causal in the expression of toxic dipeptide repeat (DPR) proteins. RAN
translation can occur in both sense and antisense reading frames [41], resulting in the production of five
different DPRs: glycine-alanine (GA), glycine-arginine (GR), proline-arginine (PR), proline-alanine (PA),
and glycine-proline (GP) [38]. Interestingly, the expression of poly-GR results in early abnormalities in
the mitochondiral respiratory chain by interacting with ATP5A1, a complex V protein, and leads to its
ubiquitination and degradation in C9orf72 ALS-FTD patients [102]. Mitochondrial dysfunction [103]
and an increased oxidative stress [104] are reported in fibroblasts and iPSC-derived astrocytes obtained
from C9orf72 ALS patients (Figure 1).
Nonfunctional and damaged mitochondria can be targeted by NIP3-like protein X (NIX) or
PTEN-induced putative kinase protein 1 (PINK1)-E3 ubiquitin ligase parkin, then sequestered into
isolation membranes and degraded after fusion with the autophagosome or lysosome [105]. Optineurin
(OPTN) and TANK-binding kinase 1 (TBK1) are key actors for mitochondria engulfment [106].
Consequently, ALS mutation in OPTN [107] and TBK1 [23] will affect the mitophagic flux and may
lead to an accumulation of nonfunctional mitochondria over time and result in motor neuron death
(see [108] for review). Taken together, except for CHCHD10, these studies point toward mitochondria
dysfunction and damage being a downstream effect of ALS gene mutations that lead to protein
aggregations and/or proteostasis dysfunction (see Section 7: Impaired Protein Homeostasis).
In addition, damage to mitochondria and alterations in their functions can disrupt calcium
homeostasis, increasing the sensitivity of neurons to glutamate excitotoxicity and the risk of motor
neuron damage ([109], Figure 1). Mitochondrial dysfunction can also activate proapoptotic signals [93],
such as the caspase-dependent [110] or bcl-2-dependant pathways [93], and might lead to motor
neuron degeneration.
4. Axonal Transport
Motor neurons have exceptionally long axons, up to 1 m in length, placing extreme demands on
cellular physiological functions that rely on the axonal transport of organelles such as mitochondria or
of molecules including proteins, lipids, and RNA to and from the synapse [111]. Axonal transport, as
well as the conduction of electrical impulses and the maintenance of the axon structure, are heavily
regulated processes linked with control of the neurofilament structure [112,113]. In both sporadic ALS
( sALS) and fALS patients, the disorganization of neurofilament networks has been reported [38].
Neurofilaments are neuron-specific intermediate filaments that are stretch-resistant and are major
cytoskeleton proteins [114]. They form parallel coiled-coiled heterotetramers composed of light,
medium, and heavy-weighted neurofilaments (NF-L, NF-M, and NF-H, respectively) and α-internexin
or peripherin [112,114]. Eight heterotetramers form cylindrical structures known as unit-length
filaments (ULFs) with the tail domains sticking out [112,114]. A series of ULFs form a filament that
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matures into neurofilament after a radial compaction of the cylindrical structure [112]. Consequently,
variants in the NEFH gene affecting the crosslinking properties of the NF-H protein may result in
abnormal neurofilament accumulations and in axonal transport defects [115].
Neurofilaments form cross-bridges not only with each other but, also, with actin filaments, actin
rings, and microtubules [114], constituing a protein network that might participate to the maintenance
of the axon structure [114,116]. Actin polymerization requires the small actin-binding proteins profilin
I and II and phosphoinositide islands localized at the membrane [117]. Mutations in the PFN1 gene
encoding profilin-I are associated with ALS [118], and the expression of mutant hPFN1G118V in a
murine model resulted in dysregulated actin polymerization [119]. Consequently, the attachement of
actin to the microtubules might be affected, probably impacting anterograde and retrograde transport
and, thus, leading to an accumulation of fragmented mitochondria and, ultimately, to upper and lower
motor neuron death ([119], Section 3 and Figure 1).
Microtubules and motor proteins such as the dynein-dynactin complex [28,120,121] and the
kinesins [120,122,123] are involved in the long-distance transport of cellular cargo. Microtubules are
composed of dimers of α- and β-tubulin. The alpha tubulin subtype TUBA4A is an ALS-associated
protein [124], and ALS-associated mutations of TUBA4A lead to microtubule polymerization defects
and network destabilization [124].
The dynein-dynactin complex [28,120,121], along with the kinesins [120,122,123], are key drivers
of the anterograde and retrograde movements of diverse cargoes along the microtubule cytoskeleton,
including organelles, vesicles, neurofilaments, AMPA and GABA receptors, and RNAs. Interestingly,
mutations in dynactin subunit 1 (DCTN1) affecting the tertiary structure of the dynactin protein and its
capacity to bind to microtubules can cause ALS [125]. When the interaction between dynein-dynactin
is interrupted by the overexpression of dynamitin, axonal transport is impaired, and mice develop
a late-onset motor pathology that recapitulates late-onset progressive ALS [126]. Kinesins form a
superfamily of molecular motors that can be divided into three groups [120]. KIF5, a member of
kinesin 1-group, is a tetramer with two kinesin heavy chains (KHCs) that contains a motor domain
and two kinesin light chains (KLCs) that facilitate connections with cargo. There are three KIF5
isoforms—KIF5A, KIF5B, and KIF5C—all three isoforms being associated with the neuronal function
and anterograde transport of proteins and organelles [127]. Mutations in the C-terminal of KIF5A,
leading to a loss of function, are associated with ALS [128] and are suspected to disrupt the axonal
transport (Figure 1). This hypothesis is supported by the defective axonal transport of mitochondria,
the local accumulation of neurofilament, and the reduced axonal growth and survival observed in the
primary culture of motor neurons from KIF5A−/− mice [129].
Distal axonal transport is also affected in SOD1G93A mice at an early stage, with an early decrease
in kinesin expression in asymptomatic mice, followed by a decrease in dynein expression in older
presymptomatic mice [130]. Defective axonal transport may contribute to the accumulation of impaired
mitochondria at distal sites ([93], Figure 1), resulting in decreased ATP production and disrupted
calcium homeostasisis at the neuromuscular junction, consequently leading to a distal axonopathy
in SOD1G93A mice [109,131,132] and SOD1 patients [24,28]. Kinesin-dynein machineries have been
described to be affected in sporadic ALS, where KIF1Bβ and KIF3Aβ, two kinesin-related proteins, were
found to be downregulated in motor cortex samples of sporadic patients [133]. However, the expression
level of another kinesin-related protein, KIFAP3, is inversely correlated with sporadic ALS patient
survival [134].
In conclusion, different mutations associated to ALS can directly alter the architecture and
dynamics of the cytoskeleton, affecting the axonal transport machinery. Interestingly, aberrant axonal
transport has also been observed in sALS patients and in fALS patients harboring mutations in
non-cytoskeletal-related genes. Disrupted transport mechanisms can then affect the mitochondrial
metabolism and degeneration (Section 3), as well as protein degradation (Section 7) and RNA transport
(Section 8), ultimately leading to motor neuron death.
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5. Glutamate Excitotoxicity
Glutamate is the most abundant neurotransmitter in the CNS and is released from presynaptic
neurons into the synaptic cleft, resulting in the activation of NMDA and AMPA receptors that
mediate calcium and sodium influxes in postsynaptic neurons. Excess glutamate may result in the
abnormal activation of glutamate receptors, causing an excessive influx of Ca2+ in the postsynaptic
neuron (Figure 1), which leads to extreme neuronal firing [135], resulting in excitotoxicity, which
is potentially implicated in a number of pathological conditions, including multiple sclerosis [136],
Parkinson’s diasease [137], and ALS [138,139]. Glutamate excitotoxicity is thought to occur as a
result of defective glutamate uptake and transport mechanisms that lead to excessive neuronal
Ca2+ intake, aberrant Ca2+ homeostasis, downstream mitochondrial dysfunction, and increased ROS
production [140,141] (Figure 1). Glutamate-gated AMPA receptors are abundant in human and animal
motor neurons [142,143] and are made up of four subunits, GluA1 to GluA4 (also GluR1–4) [144].
The overactivation of AMPA receptors has been shown to result in hindlimb paralysis and motor
neuron degeneration in wild-type rats, highlighting the susceptibility of motor neurons to Ca2+
dysregulation [145]. The Ca2+ permeability of AMPA receptors is mediated by the presence of the
GluA2 subunit, the absence of which, in addition to impaired transcriptional editing at the Q/R site,
confers increased AMPA Ca2+ permeability [146]. Interestingly, spinal motor neurons have been
reported to display a reduced expression of GluA2 relative to dorsal horn neurons from the same region,
providing some explanation for the selective susceptibiltiy of motor neurons in ALS [147], and GluA2
transcriptional editing has been found to be impaired in motor neurons of sporadic ALS patients
relative to controls [148]. Furthermore, evidence suggests that GluA2 editing is also impaired in ALS
oculomotor neurons, despite their spared function in disease. However, spared functionality has been
hypothesized to be the result of increased Ca2+-binding proteins and, in particular, parvalbumin, which
is highly abundant in oculomotor neurons and present at low levels in spinal motor neurons [149].
GluA2 transcriptional editing into the Ca2+ impermeable subunit is mediated by adenosine deaminase
acting on RNA 2 (ADAR2) activity [150,151]. A reduced ADAR2 expression has been reported in
sporadic ALS patients and has been shown to result in an increased aggregation of TDP-43 in spinal
motor neurons [152]. Taken together, the evidence suggests that a decreased GluA2 expression and
impaired transcriptional editing in spinal motor neuron AMPA receptors is a contributing factor to
the increased uptake of Ca2+ and the downstream susceptibility to excitotoxicity in ALS (Figure 1).
Moreover, the finding that AMPA receptor dysfunction can result in the aggregation of misfolded
TDP-43 is an important finding for linking ALS pathology with the glutamate excitotoxicity hypothesis.
In addition to dysregulated GluA2 subunit function, research has reported dysfunctional glutamate
transport mechanisms in ALS. Under normal physiological conditions, glutamate at the synaptic
cleft is cleared by the excitatory amino acid transporter (EAAT2), which functions to maintain low
levels of extracellular glutamate and, thus, prevent excessive increases in intracellular Na+ and Ca2+
levels [89,153]. EAAT2 is found primarely on the synaptic processes of astrocytes, and the loss of
EAAT2 has been reported to induce increased extracellular levels of glutamate and cause motor neuron
toxicity and muscle paralysis in animal models [154], whilst the pharmalogical stimulation of EAAT2
was found to rescue motor neuron degeneration and delay paralysis in SOD1G93A mice [155,156].
Abnormalaties in EAAT2 have been suggested to occur post-translationally after a post-mortem
research highlighted no differences in EAAT2 mRNA expressions between sporadic ALS patients and
controls, despite a 95% decrease in protein levels in sALS subjects [157]. Further support of EAAT2 loss
and its implications in ALS were reported by a separate group who demonstrated a reduced EAAT2
immunoreactivity in anterior horn cells of sporadic ALS and lower motor neuron disease patients
relative to healthy controls [158]. Together, these studies highlight the role of dysfunctional glutamate
uptake and transport mechanisms in sporadic cases of ALS (Figure 1).
Excitotoxicity has also been associated with genetic forms of the disease. SOD1 mutations have
been implicated in the glutamate excitotoxicity hypothesis, and research has demonstrated an increased
glutamate release [159], as well as motor neuron and inter-neuron hyperexcitability two to three months
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prior to motor neuron degeneration and phenotype onset in SOD1G93A mice [160]. SOD1 mutations have
also been shown to reduce the expression of astrocytic GluA2 in vitro and in vivo, thereby diminishing
their ability to protect against motor neuron excitotoxicity [21]. In patients, the deterioration of neuronal
dendrites was observed in sporadic and familial ALS cases, but not in healthy or Alzheimer’s disease
controls, leading to the suggestion that ALS is a synaptopathy [161], which is perhaps attributable
to the excessive levels of glutamate observed in the CSF of patients [138,139]. Indeed, metabolomic
analyses suggest that ALS patients show elevated serum levels of glutamate [32], and there is evidence
that sporadic and familial ALS cases show heightened levels of cortical excitablity, which can be
detected even in the presymptomatic stages in familial SOD1 mutation carriers [162]. However, other
studies have failed to find evidence for elevated glutamate levels in ALS patients [163–165]. C9orf72
has also been implicated in the glutamate excitotoxicity hypothesis after iPSC motorneurons from
ALS patients were found to have impaired autophagosome formation and aberrant accumulations of
glutamate receptors [166–168]. This has been supported in vivo with C9orf72 knockout mice showing
GluR1 upregulation in the hippocampus and a greater susceptibility to excitotoxicity compared to
controls [166]. In addition, C9orf72 knockout mice demonstrated a complete loss of SMCR8 [169],
a protein that functions in a complex with C9orf72 and WD40 repeat domain 41 (WDR41) to regulate
membrane trafficking and autophagy [170]. The concomitant abnormalities in autophagy and aberrant
accumulations of GluR1 has led to the hypothesis that C9orf72 loss-of-function leads to an impaired
clearance of excess glutamate receptors, which, in turn, results in a greater glutamate uptake and
increased susceptibility to excitotoxicity (Figure 1). C9orf72 patients have also been reported to
demonstrate elevated glutamate levels in their cerebropsinal fluid (CSF), which has been hypothesized
to occur as a result of DPR-mediated splicing defects to EAAT2 and subsequent impairments in
glutamate clearance [168]. Research has also implicated ALS2 in the glutamate exicitotoxicity
hypothesis by virtue of its interaction with Rab5 and the endosomal pathway. ALS2-/- knockout
mice have been reported to show significant increases in glutamate receptor degradation, including
GluA2 [171], the loss of which is believed to contribute to excitotoxicity and motor neuron degeneration.
Similarly, ALS2−/− spinal motor neurons were found to be more susceptible to glutamate excitotoxicity
as a result of reduced GluA2 at the synapses of neurons, which was attributed to an altered glutamate
receptor interacting protein 1 (GRIP1) function, caused by the genetic loss of ALS2 [171].
Although there is evidence to suggest the presence of glutamate transport and uptake defects
in both sporadic and familial cases of ALS, it is unclear how these defects lead to the specific
deterioration of motor neurons in disease. Furthermore, it has been 25 years since the approval of the
antiglutamatergic drug riluzole for the treatment of ALS, yet there is no understanding as to why it,
as well as other antiglutamatergics, including gabapentin, memantine, and ceftriaxone, fail to delay
symptom progressions in ALS by more than ~three months [172,173].
6. Endosomal Pathway and Vesicle Secretion
Extracellular vesicles encompass different types such as apoptotic vesicles, microvesicles,
and exosomes, all of which can affect the functionality of the recipient cells [174–177]. The last
decade has seen several investigations into the relevance of exosomes to ALS, either in propagating the
disease or as biomarkers [6,178–181]. In the ALS context, exosomes secreted by astrocytes, neurons,
or microglia are suspected to carry neurotoxic elements such as mutated SOD1 or C9orf72-derived
DPR and to be responsible for motor neuron death [178,179,182]. Interestingly, sporadic muscle cells
present an accumulation of vacuole and multivesicular bodies in their cytosol, suggesting that vesicle
trafficking is disrupted in these cells ([183] and personal data) and that extracellular vesicle secretion
might have an important role in ALS.
Exosome biogenesis requires the formation of inward buds in the multivesicular body (MVB),
followed by their fission and release as vesicles into the MVB lumen. The generation of intraluminal
vesicles can be either Endosomal Sorting Complex Required for Transport (ESCRT)-dependent or
ESCRT-independent. The ESCRT is composed of four complexes—ESCRT-0, ESCRT-I, ESCRT-II,
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and ESCRT-III—each complex acting one after the other to form intraluminal vesicles. Interestingly,
charged multivesicular protein 2B (CHMP2B) is a component of ESCRT-III involved in the processing
of cargo into intraluminal vesicles and is associated with ALS [184]. The dysfunction of ESCRT-III may
lead to abnormal and dysmorphic endosomes [185] (Figure 2).
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Figure 2. Protein homeostasis dysregulation. Dysregulated protein homeostasis is mediated by
multiple pathways encompassi g defects in autophagy, the dy regulated ubiquitin-proteasome system
(UPS), endo-lysosomal pathway disruptions, or endoplasmic reticulum (ER) stress. The presence of
misfolded proteins activates endoplasmic reticulum-associated protein degradation (ERAD), leading
to proteasome-mediated degradation to void misfolded protein accumulations in the ER lumen and
subsequent ER stress. Several ALS-associated gene mutations induce proteasome-mediated toxicity via
the sequestration of ubiquilin and chaperone proteins involved in the UPS pathway. The proteolytic
activity of the proteasome has also been demonstrated to be targeted by gene mutations in ALS.
The autophagic pathway involves the formation and m turation of ph g hores that e gulf selected
transported-cargo and form autophagosomes. Fusion with the lysosome enables the degradation of
autophagosome contents. Defects in autophagy initiation and expansion, dysregulated phagophore
formation, and/or impaired cargo transport are observed in ALS patients. Mutations in ALS-associated
genes also cause defects in mitophagy, a specific form of autophagy. Defects in the endolysosomal
have been associated with ALS gene mutations, including defective endolysosomal trafficking and
altered lysosomal hoemostasis and degradation. Defects in the autophagy/lysosomal pathway may
affect vesicle secretion. Genes implicated in dysregulated protein homeostasis are indicated in red. ER:
endoplasmic reticulum, ERAD: endoplasmic reticulum-associated protein degradation, ALS2: Alsin,
C9orf72: Chromosome 9 open reading frame 72, CCNF: Cyclin F, CHCHD10: coiled-coil helix coiled-coil
helix domain-containing 10, CHMP2B: chromatin-modifying protein 2B, DCTN1: Dynactin 1, FIG4:
Phosphoinositide 5-phosphatase, FUS: Fused in Sarcoma, MATR3: matrin 3, MVB: Multivesicular bodies,
OPTN: Optineurin, SOD1: Superoxide dismutase 1, SPG11: Spatacsin, TDP-43: TAR DNA-binding
protein 43, TBK1: TANK-binding kinase-1, UBQLN2: Ubiquilin-2, VAPB: vesicle-associated membrane
protein-associated protein B, and VCP: valosin-containing protein.
Endocytosis and vesicle trafficking from one cellular compartment to another are regulated
by small Rab GTPases [186]. For example, Rab5 is associated with the formation of early and late
endosomes, while Rabs 11, 35, and 27 have direct roles in exosome biogenesis and secretion. Alsin is an
ALS-associated protein [187] and is a guanine nucleotide-exchange factor involved in endosome motility
and fusion with the lysosome [171]. Consequently, an absence of alsin expression in hippocampal
neurons leads to an accumulation of Rab5-positive vesicles and an enhanced lysosome-mediated
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degradation, suggesting an enhanced degradation of endosomal vesicles [171], thus probably affecting
the production and secretion of exosomal vesicles.
The C9orf72 protein structure presents some similarities with the Differentially Expressed
Normal versus Neoplastic (DENN) guanine nucleotide exchange factor and, thus, may activate Rab
proteins [101] such as RAB8A and RAB39B [188]; Rab1a [34]; or Rabs 1, 7, and 11 [189], which are
associated with autophagy and vesicle-trafficking processes [190–192], as well as exosome biogenesis
and secretion [186]. In C9orf72 knockdown cell lines [189], a C9orf72 knockout murine model [193],
and in ALS patient fibroblasts and iPSC-derived motor neurons [194], transgolgi and endosomal
trafficking were reduced, a defective autophagy pathway was observed [34,194], and exosomal secretion
was affected [194].
Vesicle-associated membrane protein-associated protein B (VAPB) is involved in vesicle trafficking
between the endoplasmic reticulum and the golgi apparatus [195,196]. Interestingly, VAPB has been
described to interact with RAB7 and colocalize with CD63 [197], two proteins involved in late-endosome
formation and exosome biogenesis [186]. However, the impact of ALS-associated VAPB mutation in
exosome biogenesis and secretion still needs to be investigated.
Multivesicular body formation is at a crossroad between the autophagy (Figure 2) and secretion
pathways, and an autophagic failure may lead to cell secretion [198]. The VCP gene is associated with
ALS [199] and encodes for a valosin-containing protein, an ubiquitous AAA+ ATPase that interacts
with clathrin to form early endosomes but, also, with the autophagy pathways [200]. In this context,
a mutation in a valosin-containing protein (VCP) may affect the endosomal pathway, and one can
hypothesize that it has an impact on the formation and secretion of exosomes. Other gene mutations
associated to ALS, such as protein polyphosphoinositide 5-phosphatase (FIG4) [201,202] or spastacsin
(Spg11) [203,204], are associated with the blockade of lysosomal clearance (see Section 7)—the blockade
of which could potentially lead to vesicle secretion [198]. However, futher investigations related to
exosome pathways in ALS in vivo are needed.
7. Impaired Protein Homeostasis
Protein aggregates positive for TDP-43 [36,205], neurofilament [41], FUS [87], or SOD1 [206] are
observed in the vast majority of ALS patients, with TDP-43 being present in as many as 98% of sporadic
and familial cases [207], meaning that the presence of such aggregates is widely regarded as a hallmark
feature of ALS pathology. These deposits can occur in the cytoplasm of neurons [208] and skeletal
muscle [99,209], and their presence is highly suggestive of an imbalance between protein synthesis and
degradation pathways (Figure 2).
7.1. Proteasome and Autophagic Degradation Pathways
In the late 1960s and early 1970s, the presence of protein inclusions in the anterior horn cells of
sporadic and familial ALS patients was described [210–212]. Later, these inclusions were found to be
ubiquitin positive [35], and SOD1 was the first ALS-associated protein found to be immunoreactive
within the inclusions of familial patients [213]. Subsequently, ubiquinated inclusions have often been
found to be immunoreactive for the ubiquitin-binding protein p62 [214], and up to 98% of sALS
and fALS cases show inclusions that are TDP-43-positive [215], with the exception being SOD1 [216]
and FUS [216] patients who do not demonstrate TDP-43 inclusions but do demonstrate SOD1 and
FUS immunoreactive inclusions. Other ALS proteins that have been implicated in the formation
of cytoplasmic inclusions include optineurin (OPTN) [107], ubiquilin 2 (UBQLN2) [217], dynactin
1 (DNCT1) [218], valosin-containing protein (VCP) [219], and matrin 3 (MATR3) [220]. Studying
the structure of the main proteins SOD1, FUS, and TDP-43 helped to unravel potential mechanisms
involved in protein misfolding and self-propagation within the cells and in surrounding cells. SOD1
is a stable homodimer, thanks to the intrasubunit disulfide bond and its ability to bind zinc and
copper. However, a reducing and metal-poor intracellular environment or mutations [221–227] can
abolish these features and destabilize SOD1, leading to the formation of aggregates and amyloid fibril
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structures [228–231] that can self-propagate in vitro [229,230]. FUS and TDP-43 proteins possess a low
complexity domain that presents similarities with yeast prions [209] and can form large aggregates and
amyloid fibril structures [209,229,232,233]. Interestingly, mutated forms of FUS and TDP-43 can induce
the misfolding of wild type forms of FUS and TDP-43, respectively [229], and have also been shown to
induce the misfolding of wild type forms of SOD1 in vitro [234]. Altogether, these studies suggest a
potential mechanism for the self-propagation of misfolded proteins in vitro—misfolded proteins that
can potentially be transferred from cell to cell via secreted vesicles, thus propagating the misfolding
mechanism to neighboring cells (see Section 6, [178,229,235]). The presence of these protein aggregates
has been suggested to impair the proteasome and autophagic degradation pathways and could be key
mediators in ALS pathogenesis [38,236,237] (Figure 2).
Dysregulation of the Ubiquitin–Proteasome System (UPS) in ALS patients was first suspected
following the identification of mutations in genes encoding ubiquilin 2 [238] and VCP [199], two
proteins involved in protein clearance via the ubiquitin-proteasome pathway [239]. Mutations in
OPTN [240] and SQSTM1/P62 [241] were then identified, and following this, SOD1 [236], VABP [242],
C9orf72 [25,208], and CCNF (cyclin F) [243] mutations were all reported to reduce UPS activation.
Ubiquitin-positive inclusions were observed in post-mortem neuronal and muscular tissues of fALS
and sALS patients [35] and, more specifically, in C9orf72 patients [244]. Similarly, SOD1 [245], FUS [87],
ubiquilin 2 [246], and C9orf72-derived DPR proteins [247] can generate toxic aggregates positive
for some proteasome components [248]. These ubiquitin-positive inclusions can also contain and
”trap” nonmutated forms of SOD1 [48], TDP-43 [205], optineurin [107], and ubiquilin 2 [249], thus
exacerbating the already disrupted cellular homeostasis in ALS.
The degradation of ubiquitinated proteins through the autophagy/lysosomal pathway occurs in
four steps: (1) the initiation and extension of the bilayer vacuole into phagophores; (2) the transport
of selective cargoes (including ubiquitinated proteins, dysfunctional mitochondria, and protein
aggregates); (3) the maturation into autophagosomes; and (4) fusion with low pH lysosomes to form
autolysosomes where degradation of the cargoes can proceed [250].
The fusion of the endosome with the lysosome for degradation is an tightly regulated event [251]
involving the protein polyphosphoinositide 5-phosphatase, FIG4 [252]. Deleterious mutations in
FIG4 in ALS leads to abnormal lysosomal storage [201,202]. Spastacsin is also involved in lysosomal
clearance, and the absence of Spg11 expression impaired the lysosomal-autophagy pathway and is
accompanied by an accumulation of lipid within the lysosomes [203,204]. Nonfunctional TBK1 [253]
and p62 [254] inhibit the transport of targeted cargoes toward the autophagosome. Interestingly,
impaired autophagosome maturation was also observed in ALS cells mutated for FUS [255], VCP [89],
CHMP2B [184], and OPTN [256]. The importance of autophagy can be observed in studies that
stimulate autophagic activation in the presence of ALS mutations. For instance, the stimulation of
autophagy in murine and human iPSC-derived neurons expressing TARDBP mutations demonstrated
a greater clearance of TDP-43 aggregates relative to nonstimulated cells and resulted in improved
motor neuron survival [257].
C9orf72 mutations can interfere with the autophagy pathway at several levels. When C9orf72
expression is abolished or decreased as suggested by the haploinsufficiency hypothesis [258,259],
autophagy is inhibited [34,189,193,194], leading to simultaneous increases in the number of cytoplasmic
inclusions immunoreactive for ubiquitin, p62, and TDP-43 [34,101,260]. The impairment of autophagy
in C9orf72 cells may also result in the accumulation of cytotoxic DPR proteins encoded by the
G4C2 HREM and, ultimately, lead to neuronal loss [261]. Similarly to cells expressing TARDBP
mutations [257], the stimulation of autophagy abolished the accumulation of poly-DPR proteins and
neuronal toxicity [261].
Altogether, these studies illustrate the importance of autophagy for the efficient clearance of
misfolded and aggregated proteins and is indicative of the underlying impairments in proteostatic
mechanisms that mediate ALS physiopathology (Figure 2).
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7.2. Endoplasmic Reticulum Stress
During the formation of misfolded proteins, the unfolded-protein response (UPR) may be initiated
to transport defective proteins to the endoplasmic reticulum (ER), where ER-resident chaperones will
properly fold the protein [262]. The accumulation of misfolded proteins in the ER activates the ER stress
response pathway, also known as the endoplasmic reticulum-associated protein degradation (ERAD)
pathway. The ERAD pathway involves the translocation of misfolded proteins from the ER lumen to
the cytosol, where they undergo ubiquitination and degradation through the ubiquitin-proteasome
pathway [262]. In ALS patient cells, mutated SOD1 agregates were observed in ER and colocalized
with UPR markers, leading to an increase in ER stress [263] by interacting with ER stress response
proteins and inhibiting their function in the ERAD response [236]. The presence of poly (GA)
aggregates, observed in neuronal post-mortem C9orf72 ALS patients, can inhibit proteasome activity
and induce ER stress, which can be abolished when using ER stress inhibitors such as salubrinal and
tauroursodeoxycholic acid (TUDCA) [208]. Concordantly, the cerebropsinal fluid (CSF) of sporadic
ALS patients displays an accumulation of ER stress markers [263], and when healthy neurons were
exposed to patient CSF, the ER became fragmentated and caspase-dependent apoptosis was activated,
suggesting an increase in ER stress [264].
Vesicle-associated membrane protein-associated protein B (VAPB) is localized in the endoplasmic
reticulum membrane and has a key role in vesicle trafficking between the endoplasmic reticulum, golgi
apparatus, and the nuclear envelope [195–197]. The VAPBP56S mutation associated with ALS leads to a
misfolded protein that accumulates in the ER [265] and can cause a defect in nuclear envelope protein
transport, leading to an aberrant nuclear envelope structure [266]. Interestingly, the accumulation of
VAPB has also been observed in the endoplasmic reticulum of peripheral blood mononuclear cells of
sporadic ALS [267].
Optineurin is a TBK1 partner and is involved in mitophagy (Section 3). When the association of
optineurin with myosin VI is disrupted, as osberved in fALS cases associated with OPTN mutations,
optineurin is diffused in the cytosol of neuronal cells and results in ER stress and Golgi apparatus
fragmentation, as well as an inhibition of the autophagy pathway ([256], Figures 1 and 2).
Altogether, these studies suggest that protein degradation could be directly and indirectly affected
in ALS, causing protein aggregation that leads, in turn, to the disruption of the function of organelles
such as nuclei (Section 7.2) and mitochondria (Section 3) or to the blockage of lysosomal activity that
can potentially affect cell-cell communication (Section 6).
8. Aberrant RNA Metabolism
FUS [86,268] and TDP-43 [269] are RNA-binding proteins involved in multiples steps of RNA
metabolism. In ALS patients, mutations in both genes give rise to the translation of proteins frequently
mislocalized to the cytoplasm [87,88,270] and, subsequently, result in downstream complications that
affect RNA-processing mechanisms. Dysregulated RNA metabolism is another key feature of ALS
pathogenesis and includes transcription defects, alternate splicing changes, miRNA biogenesis, stress
granule formation, and RNA nucleocytoplasmic transport (Figure 3).
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8.1. RNA Splicing and Translation
Given the large number of possible protein-protein interactions between FUS or TDP-43 and
their partners, it is easy to expect alterations to important RNA-processing mechanisms in ALS
patients [89]. FUS and TDP-43 also regulate the expression of multiple proteins involved in neuronal
physiology, including components of the synaptic plasticity pathways [39,271,272] and dendritic
branching processes [272–274]. In addition, the HREM in C9orf72 generates repeat RNA and RNA
foci, which repress the gene expression of RNA metabolism regulators (such as hnRNPA3) [275] or
sequester TDP-43 [275,276] and FUS [275] proteins and, thus, indirectly inhibits the transcription
of RNA metabolism-associated genes. Similarly to C9orf72-mediated RNA-processing defects, FUS
mutations have been associated with major transcriptional defects [268].
Ataxin-2 is a polyglutamine (polyQ) protein that is involved in mRNA translation, and it interacts
with RNA-binding proteins such as TDP-43 and FUS [277]. In ALS spinal cords, ataxin 2 exhibited
significant cytoplasmic accumulation and enhanced the toxicity of TDP-43 in Drosophila via RNA
binding [59].
TDP-43, FUS, hnRNPA1, hnRNPA2B1, and MATR3 are associated with ALS and involved in
pre-mRNA processing [220,278–281]. Consequently, TDP-43 knockdown in murine tissues results in
the alternate splicing dysregulation of numerous mRNA transcripts [42,282], and the loss-of-function
of FUS also induces many splicing defects [39], suggesting important alternate splicing events in ALS
patients (Figure 3). These downstream complications are not surprising given the ability of the protein
FUS to sequester numerous components of the splicing process, such as key splicing factors [283] U1
snRNP and U11/U12 snRNPs [274,284], which are involved in minor intronic splicing. Alternative
splicing changes have been identified in neuronal genes involved in cytoskeleton organization, axonal
growth, and guidance in FUS-mutated ALS patients [285,286], and, interestingly, axonopathy and axon
retraction occur in the early stages of ALS [287].
ALS-linked MATR3S85C and MATR3P154S mutations were observed to affect Matrin 3 interactions
with the TRanscription and EXport (TREX) protein complex, altering the global nuclear export of
mRNA [288]. As a result, mRNA is sequestered within the nucleus, causing export defects of TDP-43
and FUS mRNA [288], which may affect mRNA splicing directly [289] and indirectly [278] (Figure 3).
Consequently, as observed in the MATR3S85C murine model, dysfunctional MATR3 may lead to
astrocyte and microglia activation and result in spinal motor neuron degeneration [290].
The ELP3 gene encodes for elongator protein 3, a histone acetyltransferase subunit of the RNA
polymerase II elongator complex responsible for RNA translation (Figure 3). Mutations in the ELP3
gene are associated with ALS [291,292] and result in the shortening and abnormal branching of motor
neurons, as observed in ELP3 knockdown in zebrafish embryos [291], and altered tRNA modification,
triggering proteome impairment and the subsequent aggregation of susceptible proteins [292].
Angiogenin, encoded by the hypoxia-inducible gene ANG, is a member of the pancreatic ribonuclease
superfamily [293] and, as well as angiogenesis, is also involved in ribosomal biogenesis [294,295]. Defects
in this protein are associated with the impairment of its nuclear localization and diminished ribonucleolytic
activity [295] (Figure 3), both of which are essential for normal ANG functioning and motor neuron viability.
Together, these findings suggest that RNA processing is a key pathway affected in ALS, either
due to mutations directly affecting proteins involved in RNA processing or as a consequence of
protein aggregations.
8.2. RNA Foci
Sense and antisense RNA generated from the bidirectional transcription of G4C2 repeats have
been proposed to induce a toxic gain-of-function in ALS C9orf72 patient cells by forming RNA
foci that may sequester RNA-binding proteins, thus disrupting RNA metabolism and processing
in cells [101] (Figure 3) widely throughout the central nervous system [296,297]. Both sense and
antisense RNA foci are frequently observed in nucleoli, with antisense RNA foci being denser [296].
In addition, the antisense RNA foci correlate with TDP-43 aggregation in the cytosol of C9orf72 motor
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neurons [296,297]. An in situ hybridization of post-mortem C9orf72 ALS tissue revealed that 78.7% of
the neurons and 24.9% of the glial cells in the motor brain and spinal cord regions were positive for
antisense RNA foci [297]. Interestingly, extra-motor brain regions also show a high percentage of cells
positive for antisense RNA foci, with 89.4% of neurons and 46.1% of glia being positive [297].
8.3. Epigenetic Modulation
Epigenetic mechanisms such as microRNA regulation maintain cell type and tissue identity
and may be involved in the onset and progression of neurodegenerative diseases, including ALS.
The decreased expression of miRNAs, including miRNAs let-7e, miR-148b-5p, miR-577, miR-133b,
and miR-140-3p, were observed in post-mortem spinal cords of sporadic ALS patients [298], suggestive
of impairment in the genes and pathways associated with miRNA biogenesis, neuroinflammation,
and apoptosis.
Interestingly, the class II ribonuclease, Drosha, interacts with TDP-43, FUS, and C9orf72-mediated
DPRs [299–301], while the Dicer enzyme interacts with TDP-43 protein [301] and FUS can interact
with pri-miRNA [302] (Figure 3). Consequently, mutated TDP-43 may impair the post-transcriptional
regulation of miRNAs and lead to an altered expression of miR-132-3p and miR-132-5p (involved
in the regulation of neuronal outgrowth [301]), miR-143-3p and miR-143-5p (involved in myoblast
cell differentiation [303]), miR-558-3p (involved in neurofilament stability [304]), and miR-574-3p
(associated with stroke [305]) [301]. Similarly, the downregulation of FUS in a neuroblastoma cell
line had a considerable impact on the biogenesis of miRNAs, with an altered expression of miR-9,
miR-125b, and miR-132 implicated in neuronal differentiation, activity, and function [302], while
mutated FUS affected the expression levels of miR125 and miR192 [302], which are involved in early
neural conversion [306] or senescence [307].
Altogether, these findings are consistent with defective miRNA processing in ALS patients, which
may affect downstream pathways with an impact on motor neuron survival.
8.4. Stress Granules and Nucleocytoplasmic Transport
In response to stressful conditions, RNA granules, also known as stress granules, are generated
and can recruit FUS and TDP-43 [41,308]. Mutations in FUS and TDP-43 can increase the persistence of
stress granules in the cytoplasm, resulting in a possible toxic gain-of-function [237] by inhibiting mRNA
translation and, thus, contributing to the progression of ALS pathology (Figure 3). The heterogeneous
nuclear ribonucleoprotein particle proteins hnRNPA1 and hnRNPA2B1 are RNA-binding proteins
and binding partners of TDP-43 and are involved in RNA processing, including miRNA maturation,
the nucleocytoplasmic transport of mRNA, and RNA metabolism [300,309]. Mutations in the prion-like
domains of hnRNPA2/B1 and hnRNPA1 increase fibril formation and aggregation potential, as well
their hyperassembly into stress granules [310,311]. Stress granules are then targeted to the lysosome by
the autophagic machinery involving VCP. Indeed, the pharmacological inhibition or RNAi knockdown
of VCP is accompanied by reduced stress granule clearance, while Hela cells expressing VCPA232E
and VCPR155H mutations showed a constitutive appearance and accumulation of stress granules
containing TDP-43 [312]. Concordantly, the ALS-VCP mutation is accompanied by an increase in stress
granules [313].
In C9orf72 patients, stress granules are also involved in the sequestration of proteins required for
effective nucleoplasmic transport, such as RAN GAP [40], or importing and exporting proteins [40,41].
The impairment of the nucleoplasmic transport of molecules in C9orf72 ALS cells is controverisal.
Indeed, while some studies observed that newly formed DPRs such as poly-PR can bind to nuclear
pore transporters, thereby impairing the subsequent translocation of molecules [314], other studies
did not observe any disruption in the nucleocytoplasmic transport with poly-GR or poly-PR [314].
However, with the expression of poly-GA, defects were observed both in import and in export in a
SH-SY5Y cell line and in iPSC-derived motor neurons, respectively [101].
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9. Concluding Remarks
Over 150 years have passed since ALS was first reported by Charcot, and still, the etiology of the
disease remains elusive. Although research is progressing and genetic studies continue to identify novel
gene mutations in familial cases of ALS [315], many questions remain surrounding the pathological
mechanisms associated with already established mutations, their roles in the disease phenotype, and the
as-yet-undiscovered mechanisms that underly sporadic onset. The most investigated mechanisms
revolve around neurocentric deficits in dysfunctional mitochondria and oxidative stress, axonal
transport, glutamate excitotoxity, protein homeostasis, and RNA processing (Figure 4).J. Pers. Med. 2020, 10, x FOR PEER REVIEW 18 of 36 
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Among the most studied and well-established pathways are: oxidative stress, mitochondrial dysfunction,
axonal transport, glutamate excitotoxicity, endosomal and vesicle secretions, protein homeostasis,
and RNA metabolism. One pathway may lead to another, exacerbating the disruption of cellular
homeostasis. The disruption of these pathways can lead to microglia activation, neuroinflamation,
astrocytosis, and, ultimately, to motor neuron death and muscle denervation.
By detailing, as has been done in this review, the molecular events of the various pathways that
are implicated in ALS, it becomes clear that these pathways can be linked to each other—in some cases,
with one leading to another. For example, disrupted axonal transport can lead to an accumulation of
nonfuctional mitochondria, while ATP deficiency and increased oxidative stress may damage proteins
and DNA, which, in turn, could exacerbate the disruption of cellular homeostasis, leading to motor
neuron death (Figure 4). These pathways are disrupted not only in motor neurons [24] but, also,
in astrocytes [316,317], microglia [318,319], peripheral blood cells [43,320], and muscle [37,321–323],
suggesting multisystemic [6] involvement in motor neuron death. Thus, by considering ALS from the
perspective of shared molecular pathways [6,324], a cohesive understanding may yet emerge of the
cellular mechanisms driving this pathology. It may be that different molecular pathways correspond
to sub-strata of patients, such as among those with known genetic forms of ALS, as suggested in [6].
However, the identification of these strata may prove to be extremely challenging in non-monogenic
forms of the disease [324].
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